Sone H, Okuda Y, Asakura Y, Asano M, Mizutani M, Bannai C, Yamashita K
Department of Endocrinology and Metabolism, University of Tsukuba, Japan.
Angiology. 1995 Aug;46(8):699-703. doi: 10.1177/000331979504600808.
Ibudilast is a prostacyclin-mediated vasodilator and antiplatelet agent. The hemodynamic effects of ibudilast were evaluated in 41 patients with non-insulin-dependent diabetes mellitus by means of two-dimensional Doppler ultrasonography and laser Doppler blood flowmetry. Before and one hour after oral administration of ibudilast (10 mg), or elastase (1800 U) as a control, the cross-sectional area (CSA) of the dorsal pedis artery, its blood flow index (BFI), and dermal microcirculatory blood volume (MBV) were measured. In the ibudilast group, all of the parameters (CSA, BFI, and MBV) significantly increased as compared with the elastase group. These data suggest that ibudilast is effective in ameliorating diabetic macroangiopathy and microangiopathy of the lower limbs.
异丁司特是一种前列环素介导的血管扩张剂和抗血小板药物。通过二维多普勒超声和激光多普勒血流仪评估了异丁司特对41例非胰岛素依赖型糖尿病患者的血流动力学影响。口服异丁司特（10毫克）或作为对照的弹性蛋白酶（1800单位）之前及之后1小时，测量了足背动脉的横截面积（CSA）、血流指数（BFI）和真皮微循环血容量（MBV）。与弹性蛋白酶组相比，异丁司特组的所有参数（CSA、BFI和MBV）均显著增加。这些数据表明，异丁司特在改善糖尿病下肢大血管病变和微血管病变方面有效。
